Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
You may also be interested in...
GSK/Actelion: Phase III Value Is in the Eye of the Beholder
GSK paid a very large upfront fee ($148mm) for access to Actelion's Phase III insomnia candidate almorexant, but still some were disappointed; the Big Pharma is only paying 40% of the costs of the Phase III program. The truth is that even late-stage primary care assets--especially those with novel mechanisms of action--are under intense regulatory scrutiny and licensors are having to take on more risk.
Actelion’s Tracleer Hangs On Against Label-Dampened Letairis
Edema risk with Gilead competitor probably a class effect or caused by PAH itself, analyst tells "The Pink Sheet" DAILY.
Actelion’s Tracleer Hangs On Against Label-Dampened Letairis
Edema risk with Gilead competitor probably a class effect or caused by PAH itself, analyst tells "The Pink Sheet" DAILY.